Heidelberg Pharma AG
- Biotech or pharma, therapeutic R&D
Heidelberg Pharma is a dynamic and innovative public clinical-stage biopharmaceutical company at the forefront of advancing targeted cancer therapies. Specializing in Antibody-Drug Conjugates (ADCs), our ground breaking research and development efforts focus on creating precision medicines to revolutionize cancer treatment.
Heidelberg Pharma's commitment to advancing the field of ADCs is reflected in our robust pipeline of candidates designed to selectively target cancer cells while minimizing damage to healthy tissues.
At the core of our success is our Payload Toolbox, a proprietary collection of cytotoxic payloads including RNA Polymerase II inhibitor Amanitin (ATAC®) and a cutting-edge proprietary Topoisomerase 1 Inhibitor (ETAC).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}